References
- Chegou NN, Hoek KG, Kriel M, Warren RM, Victor TC, Walzl G. Tuberculosis assays: past, present and future. Expert Rev. Anti. Infect. Ther. 9(4), 457–469 (2011).
- Telenti A, Imboden P, Marchesi F et al. Detection of rifampicin-resistance mutations in Mycobacterium tuberculosis. Lancet 341(8846), 647–650 (1993).
- Musser JM. Antimicrobial agent resistance in mycobacteria: molecular genetic insights. Clin. Microbiol. Rev. 8(4), 496–514 (1995).
- Vilchèze C, Jacobs WR Jr. The mechanism of isoniazid killing: clarity through the scope of genetics. Annu. Rev. Microbiol. 61, 35–50 (2007).
- Hillemann D, Rüsch-Gerdes S, Richter E. Evaluation of the GenoType MTBDRplus assay for rifampin and isoniazid susceptibility testing of Mycobacterium tuberculosis strains and clinical specimens. J. Clin. Microbiol. 45(8), 2635–2640 (2007).
- Huang WL, Chen HY, Kuo YM, Jou R. Performance assessment of the GenoType MTBDRplus test and DNA sequencing in detection of multidrug-resistant Mycobacterium tuberculosis. J. Clin. Microbiol. 47(8), 2520–2524 (2009).
- Ignatyeva O, Kontsevaya I, Kovalyov A et al. Detection of resistance to second-line antituberculosis drugs by use of the genotype MTBDRsl assay: a multicenter evaluation and feasibility study. J. Clin. Microbiol. 50(5), 1593–1597 (2012).
- Lacoma A, García-Sierra N, Prat C et al. GenoType MTBDRsl for molecular detection of second-line-drug and ethambutol resistance in Mycobacterium tuberculosis strains and clinical samples. J. Clin. Microbiol. 50(1), 30–36 (2012).
- Said HM, Kock MM, Ismail NA et al. Evaluation of the GenoType® MTBDRsl assay for susceptibility testing of second-line anti-tuberculosis drugs. Int. J. Tuberc. Lung Dis. 16(1), 104–109 (2012).
- Huang WL, Chi TL, Wu MH, Jou R. Performance assessment of the GenoType MTBDRsl test and DNA sequencing for detection of second-line and ethambutol drug resistance among patients infected with multidrug-resistant Mycobacterium tuberculosis. J. Clin. Microbiol. 49(7), 2502–2508 (2011).
- Helb D, Jones M, Story E et al. Rapid detection of Mycobacterium tuberculosis and rifampin resistance by use of on-demand, near-patient technology. J. Clin. Microbiol. 48(1), 229–237 (2010).
- Boehme CC, Nicol MP, Nabeta P et al. Feasibility, diagnostic accuracy, and effectiveness of decentralised use of the Xpert MTB/RIF test for diagnosis of tuberculosis and multidrug resistance: a multicentre implementation study. Lancet 377(9776), 1495–1505 (2011).
- Chang K, Lu W, Wang J et al. Rapid and effective diagnosis of tuberculosis and rifampicin resistance with Xpert MTB/RIF assay: a meta-analysis. J. Infect. 64(6), 580–588 (2012).
- Ong DC, Yam WC, Siu GK, Lee AS. Rapid detection of rifampicin- and isoniazid-resistant Mycobacterium tuberculosis by high-resolution melting analysis. J. Clin. Microbiol. 48(4), 1047–1054 (2010).
- Lee AS, Ong DC, Wong JC, Siu GK, Yam WC. High-resolution melting analysis for the rapid detection of fluoroquinolone and streptomycin resistance in Mycobacterium tuberculosis. PLoS One 7, e31934 (2012).
Websites
- Molecular line probe assays for rapid screening of patients at risk for multidrug-resistant tuberculosis (MDR-TB).www.who.int/tb/features_archive/policy_statement.pdf (Accessed 5 July 2012)
- Tuberculosis diagnostics Xpert MTB/RIF Test: WHO endorsement and recommendations.www.who.int/tb/features_archive/factsheet_xpert_may2011update.pdf (Accessed 5 July 2012)
- FIND-negotiated prices.www.finddiagnostics.org/about/what_we_do/successes/find-negotiated-prices/ (Accessed 5 July 2012)